| Revenue growth | 36% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin expanded from 21.7% to 29.8% YoY. |
| Demand visibility | High growth visibility from approved and pipeline products. |
| Management confidence | High; citing robust product pipeline and margin expansion. |
Growth
Revenue reached ₹180.2 Cr (+36% YoY); PAT stood at ₹30.7 Cr (+56% YoY). Gross margins improved to 63.5%.
Outlook
Targeting launch of 35 ANDAs (136 products) with $740mn+ gross addressable market. Significant expansion in 40+ emerging market countries.
Risks
Exposure to regulated market dependencies and potential delays in ANDA approvals/launches.
Last quarter's promises, checked
Delivered
- Guided 50% FY26 revenue growth → delivered 62% (= BEAT)
- Guided 100% FY26 PAT growth → delivered 108% (= BEAT)
- Guided ~29-31% EBITDA margin → delivered 30% (= BEAT)
Partly delivered
- Guided 30-40% revenue growth for FY27 → delivered 36% in Q1 (= PARTIAL)
Investor Presentation filed with NSE, NSE: SENORES. Summary written with AI assistance from the document.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,355.20
- Market cap
- ₹6,241 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 49.4×Sector 50.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals Price Movement Clarification
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharmaceuticals Business Update
Senores Pharma's subsidiary Apnar Pharma completed a USFDA inspection at its Vadodara facility with no GMP observations. Only one minor procedural finding was noted.
Senores Pharmaceuticals Annual Report
Senores Pharmaceuticals issued a corrigendum to its FY 2025-26 Annual Report to rectify typographical errors in the narrative and Director's Report sections. The original report remains valid.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Ltd submitted its Annual Report for FY 2025-26 and notice for its 9th Annual General Meeting scheduled for September 25, 2026.